Frontier Pharma Rheumatoid Arthritis - Cytokine Mediators Frontier Pharma Rheumatoid Arthritis | 页面 4

4.3 Epidemiology 11
4.4 Etiology 11
4.5 Pathophysiology 11
4.6 Co-morbidities and Complications 12
4.7 Diagnosis 12
4.7.1 Blood Tests 12
4.7.2 1987 Rheumatoid Arthritis Classification 13
4.7.3 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 13
4.8 Disease Progression 13
4.9 Treatment Options and Treatment Algorithm 14
4.10 Overview of Marketed Products in Rheumatoid Arthritis 15
4.10.1 Molecule Type and Molecu lar Target Analysis 15
Read Complete Report With TOC @ http://www.radiantinsights.com/research/frontier-
pharma-rheumatoid-arthritis
5 Assessment of Pipeline Product Innovation 17
5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target 17
5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by
Therapeutic Target Family 21
5.3 First-in-Class Programs Targeting Novel Molecular Targets 21
6 Signaling Network, Disease Causation and Innovation Alignment 32
6.1 Complexity of Signaling Networks in Rheumatoid Arthritis 32
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
33
6.3 First-in-Class Matrix Assessment 33
7 First-in-Class Target Evaluation 37
Follow Us: